University of Cambridge > Talks.cam > Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer > First in human evaluation of CDK9 inhibition with KB-0742 in solid tumors

  Browse A-Z

Log in

University Account External (via Google)

🔐 Log In

Information on

Subscribing to talksdetails Finding a talkdetails Adding a talkdetails Disseminating talksdetails Help and Documentationdetails

ℹī¸ Information

First in human evaluation of CDK9 inhibition with KB-0742 in solid tumors

Download to your calendar using vCal

If you have a question about this talk, please contact Kate Davenport .

Please note this seminar is on a Monday

KB-0742, is a CDK9 inhibitor, that originated from a Kronos Bio proprietary drug screen. CDK9 is a global regulator of transcription and a critical node in multiple oncogenic transcription regulated networks. KB-0742 is in an ongoing Phase 1/2 study. Details of the study will be presented.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

This talk is included in these lists:

Note that ex-directory lists are not shown.

Other lists

Average on weekdays: 9165.70202703 kWh Craik Marshall Building Decolonising the Curriculum

Other talks

Feedback and the circumgalactic medium The Importance of Teaching about Science and Religion in a Time of Global Uncertainty Title to be confirmed Animating urbanism: the demotic multiplicities of seeing cities digitally Task performance predicts the substitution of feedforward by feedback drive in visual cortex Caribbean Trip and Cacti
 

Š 2006-2025 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity